Login | Register
Profile | Log out
logo

  • Home
  • News
  • Opinion
  • Other
    • Market Updates
    • Explainers
    • Satire
  • About
  • Contact Us
    • Contact
    • Get Covered
    • Posting Guidelines
  • Subscribe
Submit An Article

biotech

  • Home
  •  
  • biotech



  • Most Read
  • Latest Comments
  • FDA approves Imugene to commence human trial for lung cancer immunotherapy
    • News

    RBA and ASIC up the ante on blockchain project, ASX writes off millions
    Public
  • FDA approves Imugene to commence human trial for lung cancer immunotherapy
    • News

    AV uptake leads Audinate to push European expansion through recruiting drive
    Public
  • FDA approves Imugene to commence human trial for lung cancer immunotherapy
    • Opinion

    What the SportsBet-BetEasy merger means for TabCorp and punters
    Public
  • FDA approves Imugene to commence human trial for lung cancer immunotherapy
    • News

    Why this Tasmanian whisky brand had a record sales quarter
    Public
  • FDA approves Imugene to commence human trial for lung cancer immunotherapy
    Tremors from the FTX collapse continue to be felt as DigitalX sells off 15% Bitcoin holdings
    • Review
    • January 10, 2023
  • Opening a new frontier in treating Parkinson’s disease
    • Review
    • November 11, 2022
  • AUDC stablecoin gathers momentum as Novatti confirms integration with XRP Ledger
    • Review
    • June 9, 2022
  • PharmAust completes dosing first cohort for MND treatment, patients respond positively
    • Review
    • January 6, 2023
  • Is this the most hated company on the ASX?
    • Review
    • August 16, 2019

Latest Articles

  • Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    Actinogen’s Phase 2a clinical trial for depression treatment fails to meet primary endpoint, shares tank
    • News

  • Holista Colltech banks on new partners to turn fortunes as food sales struggle
    Holista Colltech banks on new partners to turn fortunes as food sales struggle
    • News

  • Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    Zelira Therapeutics nears clinical trial stage for Autism drug following positive FDA feedback
    • News

  • Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    Testing methylone for PTSD treatment: Emyria’s Centre appointed site for clinical trial
    • News

  • Arovella completes development for cell therapy platform, moves to large scale manufacturing
    Arovella completes development for cell therapy platform, moves to large scale manufacturing
    • News

  • FDA approves Imugene to commence human trial for lung cancer immunotherapy
    • News

    FDA approves Imugene to commence human trial for lung cancer immunotherapy

    Biopharma company Imugene (ASX: IMU) is now on their way towards commercialisation of their lung cancer treatment with approval from the US Food and Drug Administration (FDA) to commence human trials. With the project name PD1-Vaxx in the US, the approval enables Imugene to commence recruiting patients for a clinical trial of the treatment on

    Read More
    Public
  • CLINUVEL to trial new drug addressing irreversible brain damage from by stroke
    • News

    CLINUVEL to trial new drug addressing irreversible brain damage from by stroke

    Leading pharmaceuticals company CLINUVEL (ASX: CUV) is set to commence human trials using the drug afamelanotide to dissolve or remove underlying blood clots in the brain that cause arterial ischaemic stroke (AIS) which accounts for 85% of the 15 million strokes suffered worldwide each year.  Current stroke therapies are reliant on early intervention to restore

    Read More
    Public
  • Telix submits FDA application for new prostate cancer imaging product
    • News

    Telix submits FDA application for new prostate cancer imaging product

    It may soon be easier for prostate cancer to be diagnosed at an early stage with Telix Pharmaceuticals (ASX: TLX) having submitted their radiopharmaceutical imaging technology to the Food and Drug Administration for approval. The New Drug Application (NDA) comes after completing clinical trials across more than 600 patients which builds on peer-reviewed clinical research

    Read More
    Public
  • AusCann success with medicinal cannabis for nerve pain trials
    • News

    AusCann success with medicinal cannabis for nerve pain trials

    Pharmaceuticals company AusCann (ASX: AC8) is set to progress to the next stage of clinical trials having successfully completed their first round on Neuvis, their cannabinoid-based capsule developed to treat nerve pain – an area of medicine that is inadequately met. Estimated to affect 7-10% of Australians, nerve pain is caused by damage to the

    Read More
    Public
  • Alcidion secures major UK hospital network for Patientrack health monitoring
    • News

    Alcidion secures major UK hospital network for Patientrack health monitoring

    Smart healthcare continues to make strides in the United Kingdom with healthtech company Alcidion (ASX: ALC) to deploy their Patientrack monitoring system across the NHS Lanarkshire, the third largest health board in Scotland.  With approximately 12,000 staff working across communities, health centres, clinics and three district hospitals, the 5-year agreement will see Alcidion roll out

    Read More
    Public
  • Mayne Pharma strengthens oral contraceptives portfolio in lucrative U.S market
    • News

    Mayne Pharma strengthens oral contraceptives portfolio in lucrative U.S market

    With the increasing competition amongst pharmaceutical companies being driven by a proliferation of generic brands, Mayne Pharma Group (ASX: MYX) has secured its position in the U.S as a leading oral contraceptives supplier by partnering with Novast Laboratories for 13 generic products.  Of the 13 products, four have been approved by the U.S Food and

    Read More
    Public
  • «
  • ‹
  • 8
  • 9
  • 10
  • 11
  • 12
  • ›
  • »

Login or register for free to access unlimited reading

Register Now!
  • News

  • Opinion

  • Satire

  • About

  • Contact Us

  • Subscribe

The content published on this website is solely for general information purposes and is not to be construed as financial advice. Should you seek financial advice you should consult with an appropriately qualified person. Opinions expressed on this site are subject to change without notice and The Sentiment who produced this content is under no obligation to keep the information current. The Sentiment, affiliated companies & associates may have a conflict of interest with companies discussed on the website due to commercial arrangements, for example they may be shareholders in the company, be engaged by them to assist in investor communications or receive commission/brokerage for funds raised.

Copyright © 2020 The Sentiment. All rights reserved.
Subscribe

Enter your email address below to subscribe to The Sentiment’s weekly newsletter, highlighting the top news, research, opinion and satire articles shaping ASX investor sentiment.

The Sentiment respects your privacy and will not spam you. View our privacy policy here.